CytomX Therapeutics, Inc. (CTMX) Reports Full Year 2025 Earnings
Q4 2025 loss at CytomX Therapeutics, Inc. (CTMX) widened to $0.20 per share GAAP, worse than the -$0.09 estimate (116.4% wider).
6 articles, transcripts, and reports
Q4 2025 loss at CytomX Therapeutics, Inc. (CTMX) widened to $0.20 per share GAAP, worse than the -$0.09 estimate (116.4% wider).
CytomX Therapeutics, Inc (NASDAQ: CTMX) Q2 2022 Earnings Conference
CytomX Therapeutics, Inc (NASDAQ: CTMX) Q1 2022 Earnings Conference
CytomX Therapeutics, Inc (NASDAQ: CTMX) Q4 2021 Earnings Conference
CytomX Therapeutics, Inc (NASDAQ: CTMX) Q3 2021 Earnings Conference
CytomX Therapeutics, inc (NASDAQ: CTMX) Q2 2021 Earnings Conference